Repertoire Immune Medicines signed a collaboration with Eli Lilly to develop tolerizing therapies for several autoimmune indications. The agreement provides an $85 million upfront payment and potential development and commercial milestones that could reach roughly $1.84 billion, plus tiered royalties. The deal pairs Repertoire’s immune‑repertoire discovery platform with Lilly’s development and commercialization scale. Companies cited tolerization as an approach to induce durable immune regulation rather than chronic suppression; program specifics and target indications were disclosed as autoimmune diseases broadly, with joint development governance and option terms.